Heme Flashcards
Mechanism of action of unfractionated heparin
Antithrombin III inhibits thrombin and factor Xa
5 contraindications to unfractionated heparin
Hypersensitivity Active GI bleed ICH Bacterial endocarditis HIT
Treatment of major bleeding on heparin
Stop heparin
Protamine 1 mg/100 units given over previous 4 hours, administer slowly as risk of anaphylaxis
What is HIT syndrome, diagnosis and treatment
Autoimmune response to heparin, presents as >50% reduction platelets or thrombosis. HIT assay confirms
Treat with direct thrombin inhibitor
Mechanism of action of LMWH
Inhibits factor Xa
Which patients require monitoring of factor Xa while on LMWH
GFR <50 (cleared by kidneys, needs dose adjustment)
Morbid obesity
Pregnancy
Fondaparinux: a) uses b) treatment of major bleeding c) mechanism
A) VTE, hip replacement prophylaxis
B) recombinant factor VIIa
C) inhibits factor X
Primary indication for direct thrombin inhibitors (lepirudin, bivalirudin)
Patients with HIT
No antidote exists, care is supportive
Which coagulation factors are inhibited by warfarin
II, VII, IX, X
90yo on warfarin for mechanical valve, INR is 10 with no active bleeding, how do you reverse
Hold warfarin
Vit k 2.5-5 mg po
Recheck INR
Warfarin reversal with any major bleeding
Hold warfarin
Vitamin K 10mg iv slow push (risk anaphylaxis)
FFP or PCC or recombinant factor VIIa
4 complications of warfarin
Under anticoagulation
Over anticoagulation (bleed)
Paradoxical thrombosis between 2nd and tenth day
Warfarin induced skin thrombosis
Reduce risk of last two by bridging with heparin
Mechanism of action of dabigatran, apixaban and Rivaroxaban
Dabi direct thrombin inhibitor
Rivaroxaban and apixaban factor Xa inhibitor
Management of major bleed on DOAC
Stop offending drug
Supportive management
PCC, FFP, antifibrinolytics eg tranexamic acid
What is bleeding due to with patients taking aspirin
Platelet dysfunction, not thrombocytopenia
Three classes of anti platelets and their mechanism of action
Aspirin: cox 1 inhibitor, prevents thromboxane A2 synthesis
Thienopyridines (clopidogrel): irreversibly inhibits platelet aggregation
Glycoprotein IIA/IIIb inhibitors (abciximab): inhibit platelet activation
What additives are in packed RBCs
Anticoagulant preservatives; citrate, phosphate, dextrose, adenine
How much volume is in one unit of adult and pediatric pRBCs
350 ml in adult
60 ml in peds
What should you do to reduce the risk of febrile nonhemolytic reactions and prevent sensitization in bone marrow eligible patients and reduce risk of CMV and HIV transmission in immunesuppressed
Use leukoreduced PRBCs
Indications for transfusion pRBCs
End organ damage related to anemia (ie MI, stroke)
Active or recent bleed with Hb level under 70, 80-100 in known cardiac disease
How much does one unit of pRBCs increase hemoglobin
10
Mechanism of action of tpa
Activates plasminogen to plasmin, breakdown of fibrinogen and cross linked fibrin
Define thrombocytopenia and name four causes
Platelets < 100
Decreased production, increased destruction, splenic sequestration
Transfusion threshold for platelets
Life threatening hemorrhage and abnormal platelets
Platelets under 10 (except ITP, TTP, HIT, HUS)
Bleeding under 50
Massive transfusion
Seven causes of increased platelet destruction
Immunologic: ITP HIT infection Leukaemia, lymphoma Mechanical: TTP HUS DIC HELLP
Four causes of decreased platelet production
Marrow infiltration
Drugs
Toxins
Infections
Treatment of ITP
Treat for severe bleeding under 50, platelet under 10 without bleeding
Steroids, IVIG for unresponsive to steroids, recalcitrant may need splenectomy
Platelet transfusion only for life threatening hemorrhage
Avoid NSAIDS and physical activity for two months
9 causes of DIC
Infection (most common): GP and GN sepsis, meningiococcemia, Rocky Mountain spotted fever, typhoid fever
Trauma (burns, crush, head injury)
Shock
Pregnancy complications (abruption, amniotic fluid embolus)
Transfusion and drug reaction
Carcinoma (lymphoma, leukaemia, adenocarcinoma)
Liver disease
ARDS
envenomation
Surgical procedures
Heat stroke
Laboratory findings in DIC
Coagulation product consumption: prolonged PT and PTT, low platelet, low fibrinogen, increased thrombin time
Active clot formation: elevated dimer
Microangiopathic hemolytic anemia:
Treatment of DIC
Treat underlying cause
Replace consumed coagulation factors: FFP and Cryo
Platelet transfusion under 50 of bleeding, 10 if not
If thrombosis predominated give heparin
Purpura fulminans (protein c deficiency) treat with protein c concentrate (see in severe sepsis, bruising then necrotic centre)